MA56462A - HPK1 INHIBITORS AND THEIR USES - Google Patents
HPK1 INHIBITORS AND THEIR USESInfo
- Publication number
- MA56462A MA56462A MA056462A MA56462A MA56462A MA 56462 A MA56462 A MA 56462A MA 056462 A MA056462 A MA 056462A MA 56462 A MA56462 A MA 56462A MA 56462 A MA56462 A MA 56462A
- Authority
- MA
- Morocco
- Prior art keywords
- hpk1 inhibitors
- hpk1
- inhibitors
- Prior art date
Links
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title 1
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094634 | 2019-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56462A true MA56462A (en) | 2022-05-11 |
Family
ID=74100919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056462A MA56462A (en) | 2019-07-04 | 2020-07-03 | HPK1 INHIBITORS AND THEIR USES |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220389037A1 (en) |
| EP (2) | EP3994133A4 (en) |
| JP (2) | JP2022538923A (en) |
| KR (2) | KR20220044495A (en) |
| CN (2) | CN114555585A (en) |
| AU (2) | AU2020298649A1 (en) |
| BR (1) | BR112022000064A2 (en) |
| CA (1) | CA3145973A1 (en) |
| DK (1) | DK4175951T3 (en) |
| ES (1) | ES2981368T3 (en) |
| FI (1) | FI4175951T3 (en) |
| IL (1) | IL289612A (en) |
| MA (1) | MA56462A (en) |
| MX (2) | MX2022000271A (en) |
| TW (1) | TW202116751A (en) |
| WO (2) | WO2021000935A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| JP7273172B2 (en) | 2018-10-31 | 2023-05-12 | ギリアード サイエンシーズ， インコーポレイテッド | Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2021000935A1 (en) * | 2019-07-04 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
| WO2021146370A1 (en) | 2020-01-15 | 2021-07-22 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2022063140A1 (en) * | 2020-09-23 | 2022-03-31 | Shenzhen Ionova Life Science Co., Ltd. | Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same |
| CN117024445A (en) * | 2020-10-28 | 2023-11-10 | 杭州阿诺生物医药科技有限公司 | Compounds for preparing HPK1 kinase inhibitor and synthesis method thereof |
| US20240199648A1 (en) * | 2021-03-08 | 2024-06-20 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| CN116848103A (en) * | 2021-04-08 | 2023-10-03 | 杭州阿诺生物医药科技有限公司 | High activity HPK1 kinase inhibitors |
| KR20240083168A (en) * | 2021-07-14 | 2024-06-11 | 블루프린트 메디신즈 코포레이션 | Heterocyclic compounds as MAP4K1 inhibitors |
| JP2024527623A (en) | 2021-07-20 | 2024-07-25 | アストラゼネカ・アクチエボラーグ | Substituted pyrazine-2-carboxamide inhibitors as HPK1 inhibitors for the treatment of cancer - Patents.com |
| WO2023083299A1 (en) * | 2021-11-12 | 2023-05-19 | 微境生物医药科技(上海)有限公司 | Fused ring compound as hpk1 inhibitor |
| CN118434729A (en) * | 2022-01-11 | 2024-08-02 | 微境生物医药科技(上海)有限公司 | Fused ring compounds as HPK1 inhibitors |
| WO2023245329A1 (en) * | 2022-06-20 | 2023-12-28 | Biofront Ltd | Multi-kinase inhibitors, compositions thereof, and methods of using the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007041511A2 (en) | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| JP2009542604A (en) * | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 4-Heterocycloalkylpyrimidines, their preparation and use as pharmaceuticals |
| WO2008110508A1 (en) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
| WO2012135631A1 (en) * | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| EP3096754B1 (en) * | 2014-01-22 | 2018-08-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| CN104876914B (en) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | Pyrimidine derivative type anaplastic lymphoma kinase inhibitor |
| CN106188029B (en) * | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | Two and ring class anaplastic lymphoma kinase inhibitor |
| JP6936814B2 (en) * | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Cyano-indoline derivative as an NIK inhibitor |
| WO2018049214A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| JP7025426B2 (en) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ， インコーポレイテッド | Anilinopyrimidine AS as a hematopoietic precursor kinase 1 (HPK1) inhibitor |
| WO2018152220A1 (en) * | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| CN110402248B (en) * | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | Azaindoles as HPK1 inhibitors |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US10745388B2 (en) * | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10899755B2 (en) * | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3971190A4 (en) * | 2019-05-17 | 2023-06-14 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
| WO2021000935A1 (en) * | 2019-07-04 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
-
2020
- 2020-07-03 WO PCT/CN2020/100134 patent/WO2021000935A1/en unknown
- 2020-07-03 US US17/624,514 patent/US20220389037A1/en active Pending
- 2020-07-03 TW TW109122604A patent/TW202116751A/en unknown
- 2020-07-03 BR BR112022000064A patent/BR112022000064A2/en not_active Application Discontinuation
- 2020-07-03 CN CN202080057904.1A patent/CN114555585A/en active Pending
- 2020-07-03 MA MA056462A patent/MA56462A/en unknown
- 2020-07-03 AU AU2020298649A patent/AU2020298649A1/en active Pending
- 2020-07-03 CA CA3145973A patent/CA3145973A1/en active Pending
- 2020-07-03 MX MX2022000271A patent/MX2022000271A/en unknown
- 2020-07-03 KR KR1020227003145A patent/KR20220044495A/en unknown
- 2020-07-03 JP JP2022500151A patent/JP2022538923A/en active Pending
- 2020-07-03 EP EP20834163.6A patent/EP3994133A4/en active Pending
-
2021
- 2021-07-02 EP EP21742686.5A patent/EP4175951B1/en active Active
- 2021-07-02 MX MX2023000025A patent/MX2023000025A/en unknown
- 2021-07-02 WO PCT/CN2021/104206 patent/WO2022002237A1/en active Application Filing
- 2021-07-02 ES ES21742686T patent/ES2981368T3/en active Active
- 2021-07-02 AU AU2021299849A patent/AU2021299849A1/en active Pending
- 2021-07-02 CN CN202180053862.9A patent/CN116096370A/en active Pending
- 2021-07-02 DK DK21742686.5T patent/DK4175951T3/en active
- 2021-07-02 KR KR1020237003551A patent/KR20230035061A/en unknown
- 2021-07-02 FI FIEP21742686.5T patent/FI4175951T3/en active
- 2021-07-02 US US18/013,402 patent/US20230339896A1/en active Pending
- 2021-07-02 JP JP2023500011A patent/JP2023533938A/en active Pending
-
2022
- 2022-01-04 IL IL289612A patent/IL289612A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI4175951T3 (en) | 2024-07-10 |
| CA3145973A1 (en) | 2021-01-07 |
| AU2020298649A1 (en) | 2022-02-17 |
| BR112022000064A2 (en) | 2022-05-24 |
| ES2981368T3 (en) | 2024-10-08 |
| KR20230035061A (en) | 2023-03-10 |
| JP2023533938A (en) | 2023-08-07 |
| CN116096370A (en) | 2023-05-09 |
| IL289612A (en) | 2022-03-01 |
| EP4175951A1 (en) | 2023-05-10 |
| MX2022000271A (en) | 2022-04-20 |
| WO2022002237A1 (en) | 2022-01-06 |
| JP2022538923A (en) | 2022-09-06 |
| EP3994133A4 (en) | 2023-11-22 |
| US20220389037A1 (en) | 2022-12-08 |
| KR20220044495A (en) | 2022-04-08 |
| MX2023000025A (en) | 2023-04-04 |
| WO2021000935A1 (en) | 2021-01-07 |
| EP4175951B1 (en) | 2024-05-01 |
| AU2021299849A1 (en) | 2023-02-23 |
| DK4175951T3 (en) | 2024-07-29 |
| EP3994133A1 (en) | 2022-05-11 |
| CN114555585A (en) | 2022-05-27 |
| US20230339896A1 (en) | 2023-10-26 |
| TW202116751A (en) | 2021-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56462A (en) | HPK1 INHIBITORS AND THEIR USES | |
| MA50618A (en) | POLYRHERAPIES AND THEIR USES | |
| MA55627A (en) | GLP-1R AGONISTS AND THEIR USES | |
| MA55565A (en) | STAT DEGRADING AGENTS AND THEIR USES | |
| MA47789A (en) | ANTI-PHF-TAU ANTIBODIES AND THEIR USES | |
| MA49537A (en) | ANTI-LAG3 ANTIBODIES AND THEIR USES | |
| MA52414A (en) | PD-1 AGONIST ANTIBODIES AND THEIR USES | |
| MA50256A (en) | PYRAZOLOPYRIMIDINONE COMPOUNDS AND THEIR USES | |
| MA52949A (en) | ANTI-PD-1 ANTIBODIES AND THEIR USES | |
| MA49687A (en) | ANTI-CTLA-4 ANTIBODIES AND THEIR USES | |
| MA46708A (en) | ANTI-PD1 ANTIBODIES AND THEIR USES | |
| MA45125A (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND THEIR USES | |
| MA50397A (en) | ANTI-BODY ANTI-TAU AND THEIR USES | |
| MA49886A (en) | ANTI-PAR2 ANTIBODIES AND THEIR USES | |
| MA43567A (en) | PACAP ANTIBODIES AND THEIR USES | |
| MA55083A (en) | POLYRIBONUCLEOTIDES AND THEIR COSMETIC USES | |
| MA45233A (en) | ANTI-GITR ANTIBODIES AND THEIR USES | |
| MA46704A (en) | ANTI-PYROGLUTAMATE- AMYLOID-BETA ANTIBODIES AND THEIR USES | |
| MA54693A (en) | PROSTATE NEO-ANTIGENS AND THEIR USES | |
| MA54469A (en) | ANTI-IL-27 ANTIBODIES AND THEIR USES | |
| MA52094A (en) | ANTI-IL-27 ANTIBODIES AND THEIR USES | |
| MA46945A (en) | EXOPOLYSACCHARIDES AND THEIR USES | |
| MA52365A (en) | COMPOUNDS AND THEIR USES | |
| MA55385A (en) | COMPOUNDS AND THEIR USES | |
| MA55491A (en) | ANTI-PYROGLUTAMATE-AMYLOID BETA ANTIBODIES AND THEIR USES |